Home » Topics » BioWorld Science, Neurology/psychiatric

BioWorld Science, Neurology/psychiatric
RSS

FDA clears IND application for PBFT-02 gene therapy candidate

Jan. 29, 2021

Gray matter damage in MS starts at synapses

Jan. 29, 2021

Enrollment completed in phase I/IIa study of Aggrastat in aneurysmal subarachnoid hemorrhage

Jan. 28, 2021

Astrocytic ApoE mediates memory consolidation in mice

Jan. 28, 2021

Syndesi reports phase I data on SV2A modulator SDI-118

Jan. 27, 2021

Model reveals key role of LGI1-ADAM22-MAGUK complex in transsynaptic nanoarchitecture

Jan. 27, 2021

New NFE2L2 activators patented by Senju Pharmaceutical

Jan. 26, 2021

UCB patents dopamine D1 receptor PAMs

Jan. 26, 2021

Study links ALS gene to tumor suppressor, transcription changes

Jan. 26, 2021

Neuregulin-1 beta 1 linked to early phase multiple sclerosis pathogenesis

Jan. 25, 2021

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 20, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for May 19, 2026
WHO declares Ebola outbreak a public health emergency of international concern
BioWorld
The threat posed by the Ebola outbreak in the Democratic Republic of Congo has intensified, with the confirmation that it is caused by the Bundibugyo species of...
‘Detargeted’ targeted gene therapy improves activity in Pompe
BioWorld
A new strategy aims to improve gene therapy for Pompe disease by optimizing both the genetic component that restores the function of a deficient lysosomal enzyme...
Nxera Pharma prepares and tests new GPR17 antagonists
BioWorld Science
Nxera Pharma UK Ltd. has identified new uracil nucleotide/cysteinyl leukotriene receptor (GPR17; P2Y-Like) antagonists potentially useful for the treatment of...